| Biomarker ID | 1343 |
| PMID | 24563673 |
| Year | 2014 |
| Biomarker | miR-1825 + miR-484 + PSA |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 8 PCa patients, 12 BPH patients and 10 healthy males were selected for analysis |
| Senstivity | 40% |
| Specificity | 81% |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | RT-qPCR |
| Clinical | No |
| Remarks | patients with a positive clinical diagnosis and exhibiting deregulation of either miR-1825 or miR-484 or deregulation of both were considered true positives; patients with a positive diagnosis and not exhibiting deregulation of any of the miRNAs (either separately or in tandem) were onsidered false negatives; patients with a negative diagnosis and exhibiting deregulation of either miR-1825, miR-484 or deregulation of both were con- sidered false positives; and finally, patients with a negative diagnosis and not exhibiting deregulation of either miR-1825 or miR-1825 or deregulation of both, were considered true negatives. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |